Accueil>>Signaling Pathways>> DNA Damage/DNA Repair>> Nucleoside Antimetabolite/Analogue>>2'-O,4'-C-Methylenecytidine

2'-O,4'-C-Methylenecytidine (Synonyms: LNA-C(Bz))

Catalog No.GC66654

2'-O,4'-C-Méthylènecytidine (LNA-C(Bz)) est un analogue de nucléoside bicyclique avec une conformation de type N fixe. 2'-O,4'-C-Méthylènecytidine peut être utilisé pour synthétiser des oligonucléotides. 2'-O,4'-C-Méthylènecytidine forme des duplex avec des brins d'ADN et d'ARN complémentaires.

Products are for research use only. Not for human use. We do not sell to patients.

2'-O,4'-C-Methylenecytidine Chemical Structure

Cas No.: 206055-69-8

Taille Prix Stock Qté
100mg
647,00 $US
En stock
250mg
1 109,00 $US
En stock
1g
2 248,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

2'-O,4'-C-Methylenecytidine (LNA-C(Bz)) is a bicyclic nucleoside analogue with fixed N-type conformation. 2'-O,4'-C-Methylenecytidine can be used to synthesize oligonucleotides. 2'-O,4'-C-Methylenecytidine forms duplexes with complementary DNA and RNA strands[1][2].

[1]. bicyclic nucleoside analogue, N-type conformation, synthesize oligonucleotides, duplexes
[2]. Obika S, et, al. Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2′-O,4′-C-methyleneribonucleosides. Tetrahedron Letters. 1998 Jul 23; 39(30):5401-04.

Avis

Review for 2'-O,4'-C-Methylenecytidine

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 2'-O,4'-C-Methylenecytidine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.